下载 - 辅料中国

[sanofi-aventis] (Patent
Assignee/Owner)
Gloucester Pharmaceuticals
Inc [Celgene Corp]
(Patent Assignee/Owner);
Sandoz GmbH [Novartis
AG] (Patent Assignee/Owner)
Gloucester Pharmaceuticals
Inc [Celgene Corp]
(Patent Assignee/Owner)
Gloucester Pharmaceuticals
Inc [Celgene Corp]
(Patent Assignee/Owner)
Gloucester Pharmaceuticals
Inc [Celgene Corp]
(Patent Assignee/Owner)
Fujisawa Pharmaceutical
Co Ltd [Astellas Pharma
Inc] (Patent Assignee/Owner)
Fujisawa Pharmaceutical
Co Ltd [Astellas Pharma
Inc] (Patent Assignee/Owner)
Fujisawa Pharmaceutical
Co Ltd [Astellas Pharma
Inc] (Patent Assignee/Owner)
Fujisawa Pharmaceutical
Co Ltd [Astellas Pharma
Inc] (Patent Assignee/Owner)
Fujisawa Pharmaceutical
Co Ltd [Astellas Pharma
Inc] (Patent Assignee/Owner);
National Institutes
of Health [US
Government] (Patent Assignee/Owner)
www.pharmadl.com
viii:c-containing
von-willebrand-factor and a
process for producing it
( 01-OCT-2002 )
Preparation of romidepsin WO‐2008083288
( 29-DEC-2006 )
Romidepsin-based treatments
for cancer
Gemcitabine combination
therapy
Metabolite derivatives of the
HDAC inhibitor fk228
WO‐2008083290
( 29-DEC-2006 )
WO‐2007145704
( 24-APR-2006 )
WO‐2007061939
( 18-NOV-2005 )
Antitumor agent WO‐2005079827
( 25-FEB-2004 )
Antitumor agent WO‐2005030239
( 25-SEP-2003 )
Therapeutic agent for soft tissue
sarcoma
Gene introduction efficiency
enhancer
Depsipeptide for therapy of
kidney cancer
WO‐2005000332
( 27-JUN-2003 )
WO‐2004096289
( 25-APR-2003 )
WO‐03084611
( 05-APR-2002 )
Formulation
Formulation
Component of
Combination
Formulation
Component of
Combination
New use
Component of
Combination;
New use
New use
Fujisawa Pharmaceutical Medicinal use of histone dea- WO‐03015810 New use
20 上海数图健康医药科技有限公司